The research progress of primary pulmonary mucinous adenocarcinoma
10.11904/j.issn.1002-3070.2017.05.015
- VernacularTitle:原发性肺黏液腺癌的研究进展
- Author:
Chenglu HUANG
1
;
Shaohui HAN
;
Suqin XU
Author Information
1. 中国医科大学附属盛京医院胸外科
- Keywords:
Primary pulmonary mucinous adenocarcinoma;
EGFR;
ALK;
KRAS;
Target therapy
- From:
Practical Oncology Journal
2017;31(5):463-467
- CountryChina
- Language:Chinese
-
Abstract:
Primary pulmonary mucinous adenocarcinoma with a low incidence,a subtype of lung adeno-carcinoma,occurs in adult males because of its no significant clinical specificity,likely to cause misdiagnosis,and patients with adverse prognosis.Thus,we need further to understand this disease and early diagnosis through a va-riety of methods as soon as possible.Surgical treatment is still the preferred mode of this disease.With addition to resecting lesions,it is also further pathological diagnosis,gene testing,tumor staging and prognosis as well as prep-aration for following-up chemotherapy.In recent years,with the continuous development of genetic technology and innovation,the occurrence of this disease has been found to be related to KRAS gene mutation,ALK gene re-arrangement and its related signal pathway.Related gene mutations and signaling pathways can serve as a target for the treatment of this disease,which provides a variety of ideas for the development of new targeted drugs.How-ever,there are still many problems that need further study,including standard chemotherapy for primary pulmona-ry mucinous adenocarcinoma,drug resistance to targeted drugs, and the development of new KRAS inhibitors.This article reviews the definition of primary pulmonary mucinous adenocarcinoma and pathogenesis,diagnosis and some of the latest treatment methods.
